Table 4 Independent determinants of disease-free survival among cervical cancer patients treated during 2008–2017
From: Evolution of patterns of care for women with cervical cancer in Morocco over a decade
Patients who received treatment n | Person- years of observation (PYO) n | Patients who had disease relapse n | Hazard rate per 100 PYO (95% CI) | Crude hazard rate ratio (95% CI)* | Adjusted hazard rate ratio (95% CI)** | |
|---|---|---|---|---|---|---|
Overall | 773 | 1,669 | 227 | 13.6 (11.9 - 15.5) | ||
Centre | ||||||
CM-IV, Casablanca | 261 | 547 | 125 | 22.8 (19.2 - 27.2) | 1.00 | 1.00 |
INO, Rabat | 512 | 1,122 | 102 | 9.1 (7.5 - 11.0) | 0.65 (0.52 - 0.79) | 0.35 (0.26 - 0.46) |
Period | ||||||
2008–2012 | 467 | 1,195 | 168 | 14.1 (12.1 - 16.4) | 1.00 | 1.00 |
2013–2017 | 306 | 474 | 59 | 12.4 (9.6 - 16.1) | 0.80 (0.59 - 1.03) | 0.78 (0.54 - 1.05) |
p for trend | 0.065 | |||||
Age at diagnosis (years) | ||||||
< 50 | 253 | 552 | 63 | 11.4 (8.9 - 14.6) | 1.00 | 1.00 |
50–59 | 257 | 637 | 77 | 12.1 (9.7 - 15.1) | 0.87 (0.68 - 1.09) | 1.07 (0.69 - 1.53) |
60 + | 263 | 480 | 87 | 18.1 (14.7 - 22.3) | 1.26 (0.98 - 1.53) | 1.44 (0.86 - 2.24) |
p for trend | 0.032 | |||||
Place of residence | ||||||
Urban | 524 | 1,142 | 146 | 12.8 (10.9 - 15.0) | 1.00 | 1.00 |
Semi-urban | 84 | 161 | 22 | 13.7 (9.0 - 20.7) | 1.08 (0.64 - 1.58) | 1.38 (0.76 - 2.10) |
Rural | 165 | 366 | 59 | 16.1 (12.5 - 20.8) | 1.10 (0.82 - 1.40) | 0.97 (0.68 - 1.31) |
Parity | ||||||
0–2 | 172 | 338 | 54 | 16.0 (12.2 - 20.9) | 1.00 | 1.00 |
3–4 | 192 | 466 | 55 | 11.8 (9.1 - 15.4) | 0.87 (0.64 - 1.13) | 0.81 (0.52 - 1.21) |
5 + | 359 | 820 | 106 | 12.9 (10.7 - 15.6) | 0.96 (0.78 - 1.16) | 0.78 (0.51 - 1.10) |
p for trend | 0.370 | |||||
Menopausal status | ||||||
Pre | 253 | 604 | 74 | 12.3 (9.8 - 15.4) | 1.00 | 1.00 |
Post | 462 | 977 | 134 | 13.7 (11.6 - 16.3) | 1.01 (0.83 - 1.19) | 0.93 (0.61 - 1.35) |
Stage at diagnosis | ||||||
I | 63 | 167 | 15 | 9.0 (5.4 - 14.9) | 1.00 | 1.00 |
II | 376 | 913 | 101 | 11.1 (9.1 - 13.4) | 0.80 (0.65 - 0.97) | 1.35 (0.74 - 2.27) |
III | 236 | 451 | 83 | 18.4 (14.8 - 22.8) | 1.28 (1.00 - 1.56) | 2.64 (1.44 - 4.54) |
IV | 33 | 37 | 17 | 46.1 (28.7 - 74.2) | 2.87 (1.20 - 4.57) | 6.07 (2.05 - 12.12) |
p for trend | < 0.001 | |||||
Tumour type | ||||||
Squamous cell carcinoma | 699 | 1,524 | 208 | 13.6 (11.9 - 15.6) | 1.00 | 1.00 |
Adenocarcinoma | 39 | 68 | 13 | 19.2 (11.2 - 33.1) | 1.25 (0.59 - 2.01) | 1.42 (0.67 - 2.36) |
Others | 31 | 75 | 5 | 6.7 (2.8 - 16.1) | 0.50 (0.14 - 1.03) | 0.51 (0.13 - 1.08) |
Tumour differentiation | ||||||
Well differentiated | 222 | 559 | 72 | 12.9 (10.2 - 16.2) | 1.00 | 1.00 |
Moderately differentiated | 331 | 690 | 101 | 14.6 (12.0 - 17.8) | 1.03 (0.83 - 1.25) | 1.32 (0.93 - 1.80) |
Poorly differentiated | 97 | 228 | 29 | 12.7 (8.8 - 18.3) | 0.91 (0.59 - 1.24) | 1.09 (0.64 - 1.64) |
p for trend | 0.563 | |||||
When treatment carried out | ||||||
All after registration | 642 | 1,372 | 194 | 14.1 (12.3 - 16.3) | 1.00 | 1.00 |
Both before and after registration | 104 | 265 | 24 | 9.1 (6.1 - 13.5) | 1.70 (0.09 - 4.79) | 2.72 (0.02 - 11.54) |
All before registration | 26 | 30 | 8 | 26.3 (13.2 - 52.6) | 7.51 (4.03 - 11.75) | 13.45 (2.82 - 35.23) |
Duration of symptoms (months) | 1.00 (0.99 - 1.01) | 1.00 (0.99 - 1.01) | ||||